X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ABVC would grant OncoX an exclusive global rights to develop and commercialize its oncology/hematology pipeline, including ABV-1519 for triple negative breast cancer, ABV-1501 for NSCLC, ABV-1702 for myelodysplastic syndrome and ABV-1703 for pancreatic cancer.
Lead Product(s): ABV-1519,Docetaxel
Therapeutic Area: Oncology Product Name: IND 129575
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: OncoX BioPharma
Deal Size: $105.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement April 10, 2024
Details:
Under the agreement, ForSeeCon gain access to ABVC's ophthalmology pipeline, which includes the medical device Vitargus (hyaluronic acid-derived therapy), the first biodegradable vitreous substitute to facilitate retinal reattachment surgery.
Lead Product(s): Hyaluronic Acid-derived Therapy
Therapeutic Area: Ophthalmology Product Name: Vitargus
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ForSeeCon Eye Corporation
Deal Size: $93.5 million Upfront Cash: $33.5 million
Deal Type: Licensing Agreement March 26, 2024
Details:
Under the agreement, ABVC out-licenses its CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder), including ABV-1504, a botanical reuptake inhibitor for MDD.
Lead Product(s): ABV-1504
Therapeutic Area: Psychiatry/Psychology Product Name: ABV-1504
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AiBtl BioPharma
Deal Size: $667.0 million Upfront Cash: $7.0 million
Deal Type: Licensing Agreement January 03, 2024
Details:
Under the agreement, ABVC out-licenses its CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder), including ABV-1504, a botanical reuptake inhibitor for MDD.
Lead Product(s): ABV-1504
Therapeutic Area: Psychiatry/Psychology Product Name: ABV-1504
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AiBtl BioPharma
Deal Size: $667.0 million Upfront Cash: $7.0 million
Deal Type: Licensing Agreement November 16, 2023
Details:
Under the agreement, ABVC licenses its CNS drugs, ABV-1504 and ABV-1505 with the indications of Major Depressive Disorder and Attention Deficit Hyperactivity Disorder, respectively, to AiBtl BioPharma.
Lead Product(s): Radix Polygalae Extract
Therapeutic Area: Psychiatry/Psychology Product Name: ABV-1504
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AiBtl BioPharma
Deal Size: $207.0 million Upfront Cash: $7.0 million
Deal Type: Licensing Agreement October 26, 2023
Details:
ABV-1505 (PDC-1421) is a norepinephrine transporter (NET) inhibitor indicated for attention deficit hyperactivity disorder (ADHD). It has demonstrating a highly significant 13.2-point reduction in depression as compared to a 9.2-point reduction for the placebo group.
Lead Product(s): Radix Polygalae Extract
Therapeutic Area: Psychiatry/Psychology Product Name: PDC-1421
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
PDC-1421 (radix polygalae extract) is a norepinephrine transporter (NET) inhibitor indicated for attention deficit hyperactivity disorder (ADHD). It has demonstrating a highly significant 13.2-point reduction in depression as compared to a 9.2-point reduction for the placebo group.
Lead Product(s): Radix Polygalae Extract
Therapeutic Area: Psychiatry/Psychology Product Name: PDC-1421
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2023
Details:
Under the agreement, ABVC gains exclusive licensing of ABV-1504 for Major Depressive Disorder (MDD) and ABV-1505 for Attention-Deficit/Hyperactivity Disorder in mainland China.
Lead Product(s): ABV-1504
Therapeutic Area: Psychiatry/Psychology Product Name: ABV-1504
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Xinnovation Therapeutics
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 01, 2023
Details:
The Company intends to use the net proceeds on research and development of their programs, including ABV-1501, a polysaccharide extract from Grifola frondosa Maitake mushroom, which exhibits immune-modulation effects in peripheral blood in breast cancer patients.
Lead Product(s): Grifola frondosa Maitake Mushroom Extract
Therapeutic Area: Oncology Product Name: ABV-1501
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Wilmington Capital Securities
Deal Size: $1.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 27, 2023
Details:
PDC-1421 (radix polygalae extract) is a drug product of ABV-1504, it is a botanical-based Norepinephrine Transporter (NET) inhibitor, it is being indicated for treatment of Attention-deficit/hyperactivity disorder.
Lead Product(s): Radix Polygalae Extract
Therapeutic Area: Psychiatry/Psychology Product Name: PDC-1421
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BioLite
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
